Abstract
Purpose of Review: A wide array of joint-preserving surgical techniques exists in the management of acetabular chondral defects (ACDs). The purpose of this review is to summarize the clinical outcomes of the recent biologics used to treat ACDs during hip arthroscopy. Recent Findings: Increasing evidence is available for different biological solutions used in the hip. Studies have shown promising outcomes with minimal complications when using biologics as augmentation to microfracture (MF), including different scaffolds or stem cells, or to enhance autologous chondrocyte implantation (ACI). However, data so far is scarce, and more trials and longer follow-ups are needed to better delineate the appropriate indications and benefits for each technique. Summary: Presently, the level of evidence is low, but in general, biologics appear safe and trend toward beneficial compared to standard surgical techniques. Augmented MF is recommended for small to medium ACDs, and matrix-assisted ACI or three-dimensional ACI is recommended for medium to large defects.
Original language | English |
---|---|
Pages (from-to) | 328-339 |
Number of pages | 12 |
Journal | Current Reviews in Musculoskeletal Medicine |
Volume | 14 |
Issue number | 6 |
DOIs | |
Publication status | Published - Dec 2021 |
Bibliographical note
Funding Information:Dr. Ivan Wong declares that he has received research grants from Smith and Nephew, DePuy Synthes Mitek Sports Medicine, Linvatec, and Bioventus, and personal fees from Smith and Nephew, Arthrex, Aesculap, Linvatec, and DePuy Synthes Mitek Sports Medicine, outside the submitted work.
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
ASJC Scopus Subject Areas
- Orthopedics and Sports Medicine
PubMed: MeSH publication types
- Journal Article
- Review